Cabozantinib for previously treated advanced renal cell carcinoma

  • Technology appraisal guidance
  • TA463
  • Published: 
Download guidance (PDF)

1 Recommendations

1.1 Cabozantinib is recommended, within its marketing authorisation, as an option for treating advanced renal cell carcinoma in adults after vascular endothelial growth factor (VEGF)-targeted therapy, only if the company provides cabozantinib with the discount agreed in the patient access scheme.